After years of courtroom battles, Bayer has agreed to a proposed multibillion-dollar settlement aimed at resolving thousands of U.S. lawsuits tied to Roundup, the widely used weedkiller. The cases center on claims that long-term exposure contributed to Non-Hodgkin lymphoma, allegations the company continues to dispute even as legal pressure mounts.
The settlement arrives as the U.S. Supreme Court prepares to weigh whether federal pesticide approvals should shield manufacturers from state-level failure-to-warn lawsuits. While the deal would not end that broader legal fight, it could limit Bayer’s financial exposure and offer compensation to current and future claimants, depending on how many plaintiffs opt out and whether courts approve the agreement.
For public health advocates, the development underscores a deeper concern: how regulatory assurances, corporate risk calculations and long-term chemical exposure collide — often years after products become household staples. Even as legal questions persist, the case highlights the growing gap between regulatory approvals and the lived experiences of those who say they paid the price.
SOURCE:
US Health News, February 17, 2026